Filtros de búsqueda

Lista de obras de

A Phase II, single-arm trial of neoadjuvant axitinib plus avelumab in patients with localized renal cell carcinoma who are at high risk of relapse after nephrectomy (NEOAVAX)

scientific article published on 26 April 2019

A large pooled analysis refines gene expression-based molecular subclasses in cutaneous melanoma

article

A phase II study of presurgical sunitinib in patients with metastatic clear-cell renal carcinoma and the primary tumor in situ

scientific article published on 29 July 2011

A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma.

artículo científico publicado en 2015

Absence of Programmed Death Receptor 1 Alters Thymic Development and Enhances Generation of CD4/CD8 Double-Negative TCR-Transgenic T Cells ⬇️

artículo científico publicado el 1 de noviembre de 2003

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

artículo científico publicado en 2018

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial ⬇️

artículo científico publicado en 2021

Adjuvant treatment of in-transit melanoma: Addressing the knowledge gap left by clinical trials.

scientific article published in 2022

Advanced Melanoma: Current Treatment Options, Biomarkers, and Future Perspectives.

artículo científico publicado en 2017

Age Does Matter in Adolescents and Young Adults versus Older Adults with Advanced Melanoma; A National Cohort Study Comparing Tumor Characteristics, Treatment Pattern, Toxicity and Response

artículo científico publicado en 2020

An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy.

artículo científico publicado en 2011

An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system

artículo científico publicado en 2018

Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response.

artículo científico publicado en 2014

Anti-PD1 treatment in metastatic uveal melanoma in the Netherlands

artículo científico publicado en 2016

Antitumor activity of ipilimumab after pembrolizumab in patients with advanced melanoma in KEYNOTE-006

Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial

scientific article published on 02 January 2020

Association Between Pembrolizumab-related Adverse Events and Treatment Outcome in Advanced Melanoma: Results From the Dutch Expanded Access Program

artículo científico publicado en 2019

Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1-Treated Patients in the Dutch Melanoma Treatment Registry

scientific article published on 27 January 2020

Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold

artículo científico publicado en 2019

Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold

scientific article published on 01 January 2020

Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma

scientific article published on 19 June 2020

B cells and tertiary lymphoid structures promote immunotherapy response

artículo científico publicado en 2020

BRAF(V600E) Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts

artículo científico publicado en 2016

Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab

artículo científico publicado en 2016

Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab

artículo científico publicado en 2016

Batf3+ DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy

scientific article published on 22 November 2018

Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced - or -mutated melanoma

Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro

article

CANCER IMMUNOLOGY. The "cancer immunogram".

artículo científico publicado en 2016

Cancer drug addiction is relayed by an ERK2-dependent phenotype switch

artículo científico publicado en 2017

Cancer immunotherapy: from the lab to clinical applications-Potential impact on cancer centres' organisation

artículo científico publicado en 2016

Case Report of a Fatal Serious Adverse Event Upon Administration of T Cells Transduced With a MART-1-specific T-cell Receptor

artículo científico publicado en 2015

Clinical Pharmacokinetics of Vemurafenib in BRAF-Mutated Melanoma Patients

artículo científico publicado en 2016

Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma

artículo científico publicado en 2018

Combination of targeted therapy and immunotherapy in melanoma

artículo científico

Combining checkpoint inhibition and targeted therapy in melanoma

scientific article published on 01 June 2019

Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial

scientific article published on 01 February 2019

Comparison of pre-treatment MSKCC and IMDC prognostic risk models in patients with synchronous metastatic renal cell carcinoma treated in the era of targeted therapy

artículo científico publicado en 2016

Comprehensive analysis of cutaneous and uveal melanoma liver metastases

artículo científico publicado en 2020

Concomitant targeting of programmed death-1 (PD-1) and CD137 improves the efficacy of radiotherapy in a mouse model of human BRAFV600-mutant melanoma

artículo científico publicado en 2016

Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion

artículo científico publicado en 2007

Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors.

artículo científico publicado en 2018

Cutting edge: targeted ligation of CTLA-4 in vivo by membrane-bound anti-CTLA-4 antibody prevents rejection of allogeneic cells

article

Dabrafenib for the treatment of BRAF V600-positive melanoma: a safety evaluation

artículo científico

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

artículo científico publicado en 2012

Deferred Cytoreductive Nephrectomy Following Presurgical Vascular Endothelial Growth Factor Receptor-targeted Therapy in Patients with Primary Metastatic Clear Cell Renal Cell Carcinoma: A Pooled Analysis of Prospective Trial Data

artículo científico publicado en 2020

Defining 'T cell exhaustion'

scientific article published on 30 September 2019

Dermal Delivery of Constructs Encoding Cre Recombinase to Induce Skin Tumors in PtenLoxP/LoxP;BrafCA/+ Mice

artículo científico publicado en 2016

Detection of early onset of hypophysitis by (18)F-FDG PET-CT in a patient with advanced stage melanoma treated with ipilimumab

artículo científico publicado en 2013

Determination of Sunitinib and Its Active Metabolite N-Desethylsunitinib in Sweat of a Patient ⬇️

artículo científico publicado el 1 de octubre de 2011

Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma

artículo científico publicado en 2019

Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma

scientific article published on 27 December 2018

Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma

scientific article published on 01 April 2020

ESMO consensus conference recommendations on the management of locoregional melanoma: the ESMO Guidelines Committee

artículo científico publicado en 2020

ESMO consensus conference recommendations on the management of metastatic melanoma: the ESMO Guidelines Committee

artículo científico publicado en 2020

Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells

article

Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells

Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma

scientific article published on 15 June 2019

Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanoma

scientific article published on 01 January 2020

Expression of the embryological morphogen Nodal in stage III/IV melanoma ⬇️

artículo científico publicado el 1 de diciembre de 2011

Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.

artículo científico publicado en 2017

First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis

scientific article published on 26 February 2019

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

artículo científico publicado en 2015

Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma

artículo científico publicado en 2016

Health-related quality of life of long-term advanced melanoma survivors treated with anti-CTLA-4 immune checkpoint inhibition compared to matched controls

artículo científico publicado en 2020

High-throughput identification of antigen-specific TCRs by TCR gene capture

artículo científico publicado en 2013

Homeostatic proliferation as an isolated variable reverses CD8+ T cell anergy and promotes tumor rejection

scientific article published on 01 October 2006

Homeostatic proliferation of naïve CD8+ T cells depends on CD62L/L-selectin-mediated homing to peripheral LN.

artículo científico publicado en 2009

Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma

artículo científico publicado en 2008

ICAM-1 contributes to but is not essential for tumor antigen cross-priming and CD8+ T cell-mediated tumor rejection in vivo.

artículo científico publicado en 2005

Identification of CMTM6 and CMTM4 as PD-L1 protein regulators.

artículo científico publicado en 2017

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial

artículo científico publicado en 2019

Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management.

artículo científico publicado en 2018

Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial

scientific article published on 13 May 2019

Immune resistance orchestrated by the tumor microenvironment

artículo científico publicado en 2006

Immunological heterogeneity of the RCC microenvironment: do targeted therapies influence immune response?

artículo científico

Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma

scientific article published on 02 December 2019

Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy

artículo científico publicado en 2004

Interferon-induced programmed death-ligand 1 (PD-L1/B7-H1) expression increases on human acute myeloid leukemia blast cells during treatment.

artículo científico publicado en 2013

Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts

artículo científico publicado en 2015

Ipilimumab in pretreated metastastic uveal melanoma patients. Results of the Dutch Working group on Immunotherapy of Oncology (WIN-O).

artículo científico publicado en 2013

Ipilimumab-Induced Sarcoidosis in a Patient With Metastatic Melanoma Undergoing Complete Remission ⬇️

artículo científico publicado el 28 de noviembre de 2011

LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells

artículo científico publicado en 2016

Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma.

artículo científico publicado en 2014

Lactate dehydrogenase: a marker of diminished antitumor immunity

scientific article published on 26 February 2020

Learning from clinical trials of neoadjuvant checkpoint blockade

artículo científico publicado en 2020

Letter Regarding Editorial by Samuel Zagarella

artículo científico publicado en 2020

Long-Term Survival, Quality of Life, and Psychosocial Outcomes in Advanced Melanoma Patients Treated with Immune Checkpoint Inhibitors.

artículo científico publicado en 2019

Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials

scientific article published on 01 January 2020

Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial

scientific article published on 18 September 2020

Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma

artículo científico publicado en 2014

Lower risk of severe checkpoint inhibitor toxicity in more advanced disease

artículo científico publicado en 2020

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study

artículo científico publicado en 2013

Macrophages driven to a novel state of activation have anti-inflammatory properties in mice

artículo científico publicado en 2008

Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy

scientific article published on 06 May 2020

Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis

artículo científico publicado en 2020

Metabolic targeting synergizes with MAPK inhibition and delays drug resistance in melanoma

scientific article published on 24 November 2018

Metastatic Uveal Melanoma: Treatment Strategies and Survival-Results from the Dutch Melanoma Treatment Registry

artículo científico publicado en 2019

Mimicking homeostatic proliferation in vitro generates T cells with high anti-tumor function in non-lymphopenic hosts ⬇️

artículo científico publicado el 23 de septiembre de 2012

More than 5000 patients with metastatic melanoma in Europe per year do not have access to new life-saving drugs

More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments

artículo científico publicado en 2017

Nationwide Outcomes of Advanced Melanoma According to BRAFV600 Status

artículo científico publicado en 2020

Neoadjuvant Therapy for Melanoma: A US Food and Drug Administration - Melanoma Research Alliance Public Workshop

artículo científico publicado en 2020

Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma

artículo científico publicado en 2021

Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery

artículo científico publicado en 2009

Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium

scientific article published on 01 July 2019

Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma

artículo científico publicado en 2018

Neurological immune-related adverse events of ipilimumab

Nodal as a biomarker for melanoma progression and a new therapeutic target for clinical intervention

artículo científico publicado en 2009

Non–Clear Cell Renal Cell Carcinoma: How New Biological Insight May Lead to New Therapeutic Modalities ⬇️

artículo científico publicado el 1 de junio de 2011

Observation after Cytoreductive Nephrectomy in Patients with Synchronous Not Completely Resected Metastases of Renal Cell Carcinoma

artículo científico

Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis.

artículo científico publicado en 2017

Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial

artículo científico publicado en 2018

Overall survival and PD-L1 expression in metastasized malignant melanoma

artículo científico publicado en 2010

PD-1 expression on Melan-A-reactive T cells increases during progression to metastatic disease

artículo científico publicado en 2012

PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells

artículo científico publicado en 2004

Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers.

artículo científico publicado en 2009

Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma

artículo científico publicado en 2018

Pembrolizumab versus Ipilimumab in Advanced Melanoma

artículo científico publicado en 2015

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

artículo científico publicado en 2015

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).

artículo científico publicado en 2017

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

scientific article published on 22 July 2019

Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients

artículo científico publicado en 2017

Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy)

artículo científico publicado en 2020

Phase Ib/II trial testing combined radiofrequency ablation and ipilimumab in uveal melanoma (SECIRA-UM)

artículo científico publicado en 2020

Predicting Response to Cancer Immunotherapy using Non-invasive Radiomic Biomarkers

artículo científico publicado en 2019

Predictive Immune-Checkpoint Blockade Classifiers Identify Tumors Responding to Inhibition of PD-1 and/or CTLA-4

scientific article published on 06 July 2021

Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial

artículo científico publicado en 2020

Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma

scientific article published on 11 June 2019

Progression of a caval vein thrombus in two patients with primary renal cell carcinoma on pretreatment with sunitinib

artículo científico publicado en 2010

Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab ⬇️

artículo científico publicado en 2016

Publisher Correction: Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial

artículo científico publicado en 2019

RNA interference targeting programmed death receptor-1 improves immune functions of tumor-specific T cells

artículo científico publicado en 2010

Rationalizing the pathway to personalized neoadjuvant immunotherapy: the Lombard Street Approach

artículo científico publicado en 2020

Reduced tumor‐antigen density leads to PD‐1/PD‐L1‐mediated impairment of partially exhausted CD8+ T cells ⬇️

artículo científico publicado el 23 de enero de 2012

Resection of metastasis and local recurrences of renal cell carcinoma after presurgical targeted therapy: probability of complete local control and outcome

artículo científico publicado en 2016

Restricting Glycolysis Preserves T Cell Effector Functions and Augments Checkpoint Therapy

scientific article published on 01 October 2019

Reversal of pre-existing NGFR-driven tumor and immune therapy resistance

scientific article published on 07 August 2020

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma

artículo científico publicado en 2014

Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma

artículo científico publicado en 2012

Short-term CTLA-4 blockade directly followed by PD-1 blockade in advanced melanoma patients: a single-center experience

artículo científico publicado en 2017

Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma

artículo científico publicado en 2015

Surgical Safety of Cytoreductive Nephrectomy Following Sunitinib: Results from the Multicentre, Randomised Controlled Trial of Immediate Versus Deferred Nephrectomy (SURTIME)

scientific article published on 18 June 2019

Surgical removal of the index node marked using magnetic seed localization to assess response to neoadjuvant immunotherapy in patients with stage III melanoma

scientific article published on 18 March 2019

Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events

scientific article published on 21 July 2019

Switch to checkpoint inhibition after targeted therapy at time of progression or during ongoing response: A retrospective single-centre experience in patients with BRAF-mutated melanoma

artículo científico publicado en 2019

Synchronous BRAF(V600E) and MEK inhibition leads to superior control of murine melanoma by limiting MEK inhibitor induced skin toxicity

artículo científico publicado en 2013

Systematic review of the use of granulocyte-macrophage colony-stimulating factor in patients with advanced melanoma

artículo científico publicado en 2016

Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations

artículo científico publicado en 2019

Targeted treatment and immunotherapy in leptomeningeal metastases from melanoma

artículo científico publicado en 2016

Targeting BRAF in an Inducible Murine Model of Melanoma ⬇️

artículo científico publicado el 11 de julio de 2012

Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma.

artículo científico publicado en 2016

Targeting tumor-associated acidity in cancer immunotherapy

artículo científico publicado en 2018

The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer

artículo científico publicado en 2018

The Promise of Neoadjuvant Immunotherapy and Surgery for Cancer Treatment

scientific article published on 30 April 2019

The Use of Dried Blood Spots for Pharmacokinetic Monitoring of Vemurafenib Treatment in Melanoma Patients.

artículo científico publicado en 2016

The effect of seasonal variation and secretion of sunitinib in sweat on the development of hand-foot syndrome

scientific article published on 31 August 2013

The human tumor microbiome is composed of tumor type-specific intracellular bacteria

artículo científico publicado en 2020

The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer

artículo científico publicado en 2011

Therapeutic use of anti-CTLA-4 antibodies

artículo científico

Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up

artículo científico publicado en 2020

Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma

artículo científico publicado en 2022

Vemurafenib for BRAF V600 mutated advanced melanoma: results of treatment beyond progression

artículo científico publicado en 2015

Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study.

artículo científico publicado en 2016

Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.

artículo científico publicado en 2014

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda